In conclusion, we examined the biological rationale for the use of PPAR agonists in glioblastoma, in particular brain tumor growth inhibition, glioma cell differentiation, inhibition of apoptosis, and increased catalase activity. This evidence concerns the gene CAT and central nervous system cancer.